Kornimate/medical-research-clean huggingface dataset:
virtual mindfulness rounds in the time of covid-19 pandemic

Conditions: Chronic Stress

Summary: mindfulness education will be provided via a virtual platform to see if staff stress can be decreased during this time of pandemic.

healthcare workers have been front and center in battling the covid crisis. this is a situation the researchers could never have envisioned before it happened. of course, this has triggered an inordinate amount of stress. research shows that chronic stress leaves one imbalanced and one's health and happiness to suffer. research has also demonstrated that how one thinks about stress determines how the body responds to it. simple mindfulness practices provide healthier ways to deal with stress. in this study, the researchers will introduce modified mindfulness practices that can be practiced in the healthcare setting or at home. all of the practices are based on mindfulness principles. mindfulness refers to a state of being present in the moment, on purpose, and without judgment. "mindfulness based stress reduction" is an 8 week, 2 hours/week curriculum that has shown results for over 40 years. all the practices in this study are adapted from that protocol. the intervention includes several mindfulness practices including an awareness of breath focus instruction, breath-and-body coordination and awareness instruction, and instruction in identifying times to practice these exercises. the intervention will be delivered virtually 2-day/week, twice/day, for four weeks. effectiveness will be measured by the voluntary, anonymous submission of a perceived stress scale, a validated survey tool to determine an individual's perceived stress level. participants will be healthcare workers and hospital staff in the mount sinai hospital system.

Eligibility criteria:
inclusion criteria: * mount sinai hospital employee exclusion criteria: * none

Keywords: stress mindfulness
the impact of continuous renal replacement therapy on the outcomes of burn patients with early phase of sepsis

Conditions: Burns; Sepsis

Summary: the purpose of this study is to determine if early application of crrt will result in an improvement of clinical outcomes of burn patients during the early phase of sepsis

the impact of continuous renal replacement therapy (crrt) on the outcomes of patients with sepsis is controversial, and there is no consensus for the timing and dose of crrt may improve the outcomes. the purpose of this prospective randomized study is to assess the effect of different crrt intensity (25ml/kg/h or 50ml/kg/h) on the outcomes of burn patients with early phase of sepsis

Eligibility criteria:
inclusion criteria: * patients with documented sepsis * clinically identified focus of infection associated with at least 2 sirs -criteria and one or more sepsis-induced organ failures within the 24 hours -prior to inclusion * age 18 to 70 years * severe burned patients with 50% \< tbsa \< 85% exclusion criteria: * cirrhosis child class c * too high apache ii \& sofa score at admission * age over 70 years * were presence of a malignant tumor, chronic renal insufficiency (serum creatinine \> 133 µmol/l), moribund state, receiving immunosuppressive therapy or receiving any kind of renal replacement therapy before randomization
ridge preservation in mandibular molars using mixture of abb and autogenous particulate vs sticky bone

Conditions: Alveolar Bone Loss; Bone Graft Failure; Alveolar Bone Resorption

Summary: histological measurement comparing the density of the new bone formed during socket preservation technique using a mixture of anorganic bovine bone(abb) and autogenous particulate vs a mixture of injectable platelets rich fibers, abb and autogenous particulates (sticky bone). radiographical measurements of the amount of bone dimensions changes in socket preservation technique in 6-month period using a mixture of anorganic bovine bone(abb) and autogenous particulate vs a mixture of injectable platelets rich fibers, abb and autogenous particulates (sticky bone)


Eligibility criteria:
inclusion criteria: * adult patients with hopeless mandibular molars indicated for extraction and implant placement in two stages that indicate socket preservation. * both sexes. * no intraoral soft and hard tissue pathology. * no systemic condition that contraindicate implant placement. exclusion criteria: * presence of fenestrations or dehiscence of the residual bony walls after extraction. * heavy smokers more than 20 cigarettes per day .(24) * patients with systemic disease that may affect normal healing. * psychiatric problems * disorders to implant are related to history of radiation therapy to the head and neck neoplasia, or bone augmentation to implant site. * patients that refuse to be called back for implant placement post extraction. * patients that have exceeded bone resorption surrounding the tooth prior to extraction and require guided bone regeneration.
levosimendan infusion in critically ill patients with cardiogenic shock

Conditions: Cardiogenic Shock; Cardiorenal Syndrome; Acute Kidney Failure

Summary: to determine whether levosimendan infusion in patients with cardiogenic shock and cardiorenal syndrome refractory to standard inotropic therapy, improves hemodynamics and renal function, whilst being safe.

cardiogenic shock or the state of systemic hypoxia albeit initially preserved intra-vascular volume and intact vascular function, is solely the result of insufficient cardiac output \[1-2\]. the ensuing centralization and redistribution of blood-volume, is induced by a stimulation of the renin-angiotensin system, as well as vasopressin and endogenous catecholamine liberation \[2-3\]. precipitating cardiogenic shock has a direct effect on the kidney, also called the cardiorenal syndrome \[4\]. the overall consensus for the therapy of cardiogenic shock is the use of inotropes to increase cardiac output and reverse organ hypoxia \[2\], nevertheless their increase of myocardial and glomerular oxygen consumption make them a double edged sword to use in cardiogenic shock and more prominently in cardiogenic shock coupled with pronounced cardiorenal syndrome. levosimendan is an inotropic agent that was developed for the treatment of severely decompensated heart failure. it exerts its inotropic effects primarily through sensitizing troponin c to calcium and thereby increasing contraction of cardiac myofilaments during systole \[5\]. unlike other inotropic agents, levosimendan acts independently of the beta adrenergic receptor \[5\]. additionally, the effect of levosimendan could be beneficial for the kidneys function by decreasing pre-glomerular arteriolar vasotonus whilst keeping post-glomerular arteriolar vasotonus constant \[6\]. in light of the scarce but promising literature the question arises if levosimendan can safely ameliorate cardiac and renal function concomitantly in patients presenting the combination of cardiogenic shock and cardiorenal syndrome.

Eligibility criteria:
inclusion criteria: * levosimendan * cardiogenic shock * continuous monitoring of cardiac output at the start of and during treatment with levosimendan exclusion criteria: * extracorporal hemodynamic support or an implanted ventricular assist device * previous therapy with levosimendan during the index hospitalization * refusal of participation in the study

Keywords: levosimendan inotropic agent
diet, hepcidin, and chemotherapy rdi

Conditions: Breast Cancer Female; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Endometrial Cancer; Gynecologic Cancer

Summary: this prospective, observational cohort study will evaluate the extent of associations between self-reported pro- or anti- inflammatory dietary intake patterns for one month before induction chemotherapy for gynecological cancer or neo/adjuvant chemotherapy for breast cancer and baseline serum hepcidin concentrations. associations between hepcidin concentration and relative dose intensity (rdi) of chemotherapy will also be evaluated.

this is a prospective, observational cohort of 100 women receiving chemotherapy for breast or gynecological cancer at gw cancer center from july 1, 2024 - approximately september 2025. at study baseline (after diagnosis, but prior to starting chemotherapy), participants will complete a \~30-minute food frequency questionnaire (ffq) and demographic/food security survey using a preprogrammed ipad in the clinic. the clinical research nurse will obtain an additional research blood draw at the same time as the patient's routine clinical blood draw prior to chemotherapy initiation for serum hepcidin concentration measurement. data on cancer type, premorbid medical conditions, and chemotherapy plans and administration will be collected from the electronic health record by study staff and the duration of data collection will be the length of chemotherapy plus 30 days. data will be used to address the objectives below. among adult women scheduled to receive chemotherapy for breast or gynecological cancer treatment, the objectives/aims of this study will be to: 1. determine the extent to which pretreatment, self-reported dietary inflammatory index dietary pattern scores from dietary intake during the one month prior to chemotherapy initiation are associated with pretreatment serum hepcidin concentrations 2. determine the extent to which pretreatment serum hepcidin concentrations are associated with chemotherapy rdi.

Eligibility criteria:
inclusion criteria: * have been diagnosed with invasive breast cancer, or * have been diagnosed with epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, or * have been diagnosed with endometrial cancer * are chemotherapy-naïve * are scheduled to receive neoadjuvant chemotherapy (or adjuvant chemotherapy following lumpectomy for breast cancer patients) or neoadjuvant/induction chemotherapy for gynecological cancer at gw cancer center exclusion criteria: * prior primary hematological condition that would cause abnormal blood counts (e.g. leukemia) * pregnant at the time of potential enrollment * receipt of erythropoietin-stimulating agents or blood transfusion in the 6 weeks prior to initial testing * women who are cognitively unable to provide a diet history for the month prior to assessment.

Keywords: nutrition inflammation anemia toxicity chemotoxicity
slide interpretation or standard surgical pathology in assessing margin status in patients with pancreatic cancer undergoing surgery

Conditions: Pancreatic Cancer; Adenocarcinoma

Summary: this study is being done to investigate another way of evaluating margin status after pancreatectomy by using cytopathology (slide interpretation) as compared to the traditional method of surgical pathology

primary objectives: i. to compare margin status on final pathology with margin status from cytopathologic evaluation. outline: patients undergo cytopathologic sample collection during pancreatic resection during which slides are gently pressed against the cut edge of the pancreas, the surgical bed, and along the superior mesenteric artery, and finally against the tumor itself.

Eligibility criteria:
inclusion criteria: * patients undergoing pancreatic resection for a presumed, although not necessarily biopsy-proven pancreatic malignancy, * ages 18 years to 80 years old exclusion criteria: * pregnant women

Keywords: pancreatic cancer adenocarcinoma pancreatic resection
treatment of respiratory complications associated with covid-19 using umbilical cord mesenchymal stromal cells

Conditions: Covid19

Summary: this is a randomized phase ii placebo controlled clinical trial. active arm: allogeneic wharton's jelly derived mscs (wj-mscs). both groups will receive standard of care treatment for covid (e.g. dexamethasone)

allogeneic wharton's jelly-mscs (wj-msc) will be provided by nextcell pharma under the commercial name of protrans®. protrans® will be administered at a fixed dose of 100 million cells per patient in a single infusion at bedside. placebo: sodium chloride buffer supplemented with 5% hsa and 10% dmso same volume and mode of administration as treatment group (nextcell pharma).

Eligibility criteria:
inclusion criteria: * male or female, aged 18 years-old or older * laboratory-confirmed sars-cov-2 infection determined by reverse-transcription polymerase chain reaction (rt-pcr) prior to randomization * hospitalized patients * severe covid-19 pneumonia defined as patients who cannot saturate \> 96% on 4 l/min but are not on "non-invasive" ventilation nor invasive mechanical ventilation nor extracorporeal membrane oxygenation (ecmo). patients on high flow would be eligible if they receive treatment in a non-critical care unit only. * use of contraception or acceptable birth control for the duration of the study in women of childbearing potential * provision of written or verbal informed consent by the patient or designated substitute decision maker exclusion criteria: * inability to provide informed consent * patients expected to survive less than 24 hours * advanced directives of patient's wishes to refuse intubation. * patients on mechanical ventilation * pregnant women \[pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin (hcg) laboratory test\] * breastfeeding * weight \> 100 kg or \< 50 kg * cancer not in remission or active serious illness unrelated to covid-19. * any of the following laboratory results at screening: absolute neutrophil count (anc) ≤ 1.0 x 109/l, platelets (plt) \ 5n, egfr \< 30 ml/min * current documented bacterial infection * known infection with human immunodeficiency virus, treponema pallidum, hepatitis b antigen (serology consistent with previous vaccination and a history of vaccination is acceptable) or hepatitis c * on-going therapy against tuberculosis, or exposed to tuberculosis or have travelled in areas with high risk of tuberculosis or mycosis within the last 3 months * known allergies to a component of the protrans® product * pre-existing chronic respiratory diseases requiring long-term oxygen therapy or severe pulmonary hypertension (paps \>30 mm hg) or pulmonary fibrosis * pre-existing cirrhosis with basal child and pugh of c

Keywords: mesenchymal stromal cells wharton's jelly respiratory complication biologics
does esp block reduce pain and opiates consumption after surgery

Conditions: Post Operative Pain; Regional Anesthesia Morbidity; Opioid-Related Disorders; Chronic Pain

Summary: the patients will be randomly assigned to standard therapy or standard therapy+esp nerve block. after surgery pain level and narcotic consumption will be measured, and vital signs and side effects will bo monitored for up to 72 hours. 6 months after surgery a phone interview will be conducted to asses chronic pain

patients will be divided randomly into two groups before the beginning of operation: group 1: patients will be treated to standard pain control treatment ; group 2: patients will receive erector spinea block (30-40 ml ropivacaine 0.375% plus 2 mg dexamethasone injection using ultrasound approach) additionally to standard pain control treatment the esb (erector spinae plane block) will be performed at the beginning of the procedure while the patient under general anesthesia, in assistance of ultrasound for visualization, anesthetic injection 30-40 ml ropivacaine 0.375% plus 2 mg dexamethasone administered on each side between thoracic transversus process and longitudinal spinea muscle. in the the postoperative care room, the vital sings and pain level will be continuously monitored. during the postoperative period stay the pain level of each patient will be assessed by of visual analog score of pain (vas: 0-10) interviewing the patient every 30 minutes from the patient's admission from operation room and thereafter every 1 - 4 -8 -12 -24 -48 - 72 hours, at discharge, 7- 14-21 days. for a more accurate assessment of pain, a pre-operative baseline level of pain eill be recorded. any postoperative pain will be routinely managed by 5-10 mg of intravenous morphine to achieve a vas scale of none or mild pain (1-5). investigators will also continue to record events of postoperative nausea and vomiting (ponv) within 24 hours after procedure. the ponv will be assessed by the ponv impact scale score, based on numerical responses to questions. a ponv impact scale score of ≥5 defines clinically relevant ponv. recording of urinary retention, constipation, opioid requirements and itching will also be preformed. after 3 and 6 months a telephone survey will be preformed - recording pain related to surgery and to asses chronic pain syndrome. during the phone conversation, patients will be asked to answer by the brief pain inventory.

Eligibility criteria:
inclusion criteria: 1. all patients undergoing thoracic surgery, older ≥18 years 2. patients who meet criteria of asa (american society of anesthesiologists) physical status i-ii-iii class. exclusion criteria: 1. patients who will be unconscious or mentally incompetent 2. patients refusal to participate in the study 3. asa -iv -v 4. patient with coagulopathy 5. hemodynamically unstable (systolic blood pressure \ 100) 6. allergy to local anesthetic drugs or opioids 7. pregnant patient 8. history of opioid abuse

Keywords: erector spinea block post operative pain post operative opioid consumption post operative chronic pain opioids side effects
non-interventional extension to investigate recurrence of vulvovaginal candidiasis and candida colonization

Conditions: Candidiasis, Vulvovaginal; Yeast Infection; Mycoses; Moniliasis, Vulvovaginal; Vaginitis, Monilial

Summary: non-interventional extension study to investigate vvc recurrence and candida colonization following the p2 acute vvc study

following completion of the phase 2, multicenter, randomized, active-controlled study of the safety and tolerability of two formulations of cd101 compared to fluconazole for the treatment of moderate to severe episodes of acute vulvovaginal candidiasis (nct07299432), subjects without a recurrence of vvc will be followed up to an additional 90 days +/- 14 days to assess candida colonization and recurrence of vvc.

Eligibility criteria:
inclusion criteria: * enrollment in and completed the primary study through the day 28 visit. * received at least one dose of study drug in the primary study * able to give written informed consent prior to completion of the primary study exclusion criteria: * received systemic or topical vaginal non-study antifungal therapy at any time during the primary study * diagnosed with bacterial vaginosis, trichomonas, gonorrhea, chlamydia, or active herpes at any point during the primary study * the principal investigator considers that the subject should not participate in the study
impact of tmao serum levels on hyperemic imr in stemi patients

Conditions: STEMI - ST Elevation Myocardial Infarction; Microvascular Coronary Artery Disease

Summary: trimethylamine n-oxide (tmao) is a gut microbiota-dependent metabolite of dietary choline, l-carnitine, and phosphatidylcholine-rich foods. on the basis of experimental studies and patients with prevalent disease, elevated plasma tmao may increase risk of atherosclerotic cardiovascular disease (ascvd). however, to our knowledge, no data is available on its impact on coronary microcirculation.


Eligibility criteria:
inclusion criteria: 1. patient diagnosed with stemi 2. availability of non- left anterior descending artery (lad) non culprit lesion, which is planned for a staged percutaneous coronary intervention (pci) exclusion criteria: 1. patient undergoing cardiopulmonary resuscitation; 2. patients with a history of old myocardial infarction or history of coronary artery bypass grafting (cabg) or percutaneous coronary intervention pci 3. patients with signs of chronic infection, prolong usage of corticosteroids or compromised immune system 4. patients had thrombolysis before primary percutaneous coronary intervention (ppci) 5. had contraindication of adenosine triphosphate (atp); 6. had a history of liver or renal function dysfunction 7. patients with dementia 8. patients being referred to cabg after primary pci 9. unable to provide informed consent; 10. had pregnancy or life span \< 1 year. 11. presence of sever structural valvular heart disease 12. presence of significant left main disease 13. unability to measure the index of microcirculatory resistance due to (death or retraction from the study ...etc) 14. inability to perform successful pci
platelet activation affecting the rate of vascular access patency

Conditions: Platelet Activation; Hemodialysis Fistula Thrombosis

Summary: in the case of cardiovascular diseases such as coronary artery disease, cerebrovascular disease, and peripheral arterial disease, there are many studies that the use of antiplatelet agents is very helpful in improving the vascular patency rate, but there are not many studies on the use of antiplatelet agents in the dialysis approach. the basis for use is insufficient. there is a lack of research on whether maintaining a state in which platelet activation is suppressed is helpful in improving dialysis access patency. therefore, we conducted this study to determine whether the degree of platelet activation affects the patency of vascular access.


Eligibility criteria:
inclusion criteria: * patients 19 years of age or older who are undergoing hemodialysis during renal replacement therapy * patients undergoing arteriovenous fistula formation and hemodialysis to the affected area * patients who have the ability and willingness to consent to participate in the clinical study, have signed the consent form in accordance with the appropriate procedures, and can visit and participate in the clinical study as planned exclusion criteria: * patients who failed to start hemodialysis with an arteriovenous fistula within 3 months * patients who have had stent implantation or surgery during the study period due to cardiovascular disease * patients with severe hepatic impairment * patients with coagulopathy and liver disease associated with clinically significant bleeding risk * patients with clinically significant bleeding or bleeding risk * patients who underwent artificial heart valve replacement requiring anticoagulant administration * patients with pulmonary embolism who are hemodynamically unstable or require thrombolysis or pulmonary embolization. * pregnant and lactating women
project powerfood: promoting food security, equity, and health

Conditions: Diabetes; Obesity

Summary: project powerfood is a pilot program aimed at addressing food insecurity and food access in primary care through the implementation of a food prescription program in collaboration with a number of community partners. the objectives of this project are: 1. implement screening for food insecurity in adult and pediatric primary care practices at mount sinai. 2. provide fresh fruit and vegetable "prescriptions" to be redeemed for farm shares from local partner, the corbin hill food project. prescriptions will provide 50% off of a fruit and vegetable box. participants will have the option to purchase 2 boxes per month for 6 months. 3. pilot prescriptions with 50 adult patients with poorly-controlled diabetes and 50 obese children who are food insecure and/or receive snap and/or wic benefits. examine/evaluate: 1. feasibility of program in a busy primary care practice 2. outcomes before and after the intervention (at baseline, 6 and 12 months), including diet, diabetes control, and body mass index (bmi) 3. outcomes in a comparison group (that will receive the food prescriptions beginning at 6 months)


Eligibility criteria:
inclusion criteria: * food insecure and/or receive snap and/or wic * adult patients: poorly-controlled diabetes (hemoglobin a1c greater than 8.0%) * pediatric patients: obesity, ages 5-11 * speak english or spanish exclusion criteria: * food secure and do not receive snap or wic * adult patients: do not have diabetes * pediatric patients: not obese, under 5 years old or between 11 and 18 * speak neither english or spanish * severe kidney disease (chronic kidney disease (ckd stage iv or v)

Keywords: food insecure